al01211
Small moleculeexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 8, 2021 (NCT04908462)
Timeline
Indications
Mechanism of action
- Ceramide glucosyltransferaseINHIBITOR
UGCG inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06114329 | Phase 2 | Oct 25, 2023 | AceLink Therapeutics, Inc., Jiao Tong University, Tigermed Consulting Co., Ltd |
| NCT04908462 | Phase 1 | Jun 8, 2021 | AceLink Therapeutics, Inc., Novotech, Nucleus Network Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AceLink Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2021 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Novotech | For profit | 1 | 0 | 1 | 2021 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2021 |
| Tigermed Consulting Co., Ltd | For profit | 1 | 0 | 1 | 2023 |
5 organizations
Page 1 / 1